EVIDENCE LIBRARY
Why TSPO ligand effects and gene-deletion results did not always agree
A review of the former peripheral benzodiazepine receptor highlights uncertainty in assigning a drug effect to its presumed target.
A review of the former peripheral benzodiazepine receptor highlights uncertainty in assigning a drug effect to its presumed target.
Two ways of studying a target
The review contrasts pharmacological experiments using TSPO-binding ligands with genetic studies that reduce or remove TSPO. Some findings from animal and cellular models challenged expectations about its functions and the mechanisms of ligand effects.
The discrepancy matters because a molecule binding a protein does not establish that every observed downstream effect is caused exclusively through that protein.
Historical nomenclature can mislead
TSPO’s older name, peripheral benzodiazepine receptor, does not make its biology interchangeable with central benzodiazepine modulation of GABA-A receptors. The review concerns mitochondrial and inflammatory research, not a new clinical sedative trial.
For evidence interpretation, distinguish target binding, genetic dependence, and functional outcome. The paper supports caution when assigning mechanism from ligand studies alone. It does not establish that familiar prescribed benzodiazepines share every effect attributed to experimental TSPO ligands.
Source paper
Original analysis of the supplied journal article, identified as PMC6999824.